Država: Evropska unija
Jezik: angleščina
Source: EMA (European Medicines Agency)
inclisiran
Novartis Europharm Limited
C10AX
inclisiran
Lipid modifying agents
Hypercholesterolemia; Dyslipidemias
Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Revision: 5
Authorised
2020-12-09
25 B. PACKAGE LEAFLET 26 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LEQVIO 284 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE inclisiran This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Leqvio is and what it is used for 2. What you need to know before you are given Leqvio 3. How Leqvio is given 4. Possible side effects 5. How to store Leqvio 6. Contents of the pack and other information 1. WHAT LEQVIO IS AND WHAT IT IS USED FOR WHAT LEQVIO IS AND HOW IT WORKS Leqvio contains the active substance inclisiran. Inclisiran lowers levels of LDL-cholesterol (“bad” cholesterol), which can cause heart and blood circulation problems when levels are raised. Inclisiran works by interfering with RNA (genetic material in body cells) to limit the production of a protein called PCSK9. This protein can increase LDL-cholesterol levels and preventing its production helps to lower your LDL-cholesterol levels. WHAT LEQVIO IS USED FOR Leqvio is used in addition to your cholesterol-lowering diet if you are an adult with a high cholesterol level in your blood (primary hypercholesterolaemia, including heterozygous familial and non-familial, or mixed dyslipidaemia). Leqvio is given: - together with a statin (a type of medicine that treats high cholesterol), sometimes combined with another cholesterol-lowering treatment if the maximum dose of the statin does not work well enough, or - alone or together with other cholesterol-lowe Preberite celoten dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Leqvio 284 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains inclisiran sodium equivalent to 284 mg inclisiran in 1.5 ml solution. Each ml contains inclisiran sodium equivalent to 189 mg inclisiran. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). The solution is clear, colourless to pale yellow, and essentially free of particulates. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months. _Missed doses _ If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing continued according to the patient’s original schedule. If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months. _ _ _ _ 3 _Treatment transition from monoclonal antibody PCSK9 inhibitors_ Inclisiran can be administered immediately after the last dose of a monoclonal antibody PCSK9 Preberite celoten dokument